{"id":53276,"date":"2025-06-06T09:14:25","date_gmt":"2025-06-06T08:14:25","guid":{"rendered":"https:\/\/www.elixirr.com\/en-us\/?p=53276"},"modified":"2025-10-31T10:02:01","modified_gmt":"2025-10-31T10:02:01","slug":"breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly","status":"publish","type":"post","link":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/","title":{"rendered":"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Why now?<\/strong><\/h2>\n\n\n\n<p>In 2025, biopharma is caught in a squeeze.<\/p>\n\n\n\n<p>R&amp;D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a surge in biosimilar competition, and the stakes for innovation have never been higher.<\/p>\n\n\n\n<p>Meanwhile, many organizations remain trapped in legacy operating models\u2014unable to translate scientific potential into enterprise value. Too many teams are still \u201cworking hard,\u201d but not \u201cmoving fast.\u201d<\/p>\n\n\n\n<p>The signal is clear: the market no longer rewards effort. It rewards results.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Breakthrough isn\u2019t a buzzword \u2013 it&#8217;s a benchmark<\/strong><\/h2>\n\n\n\n<p>At Elixirr, we define breakthrough as results that wouldn\u2019t happen without a fundamental shift. For biopharma leaders, that means:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Accelerating product development timelines\u2014not just hitting milestones, but recovering slipped timelines and achieving first-to-market advantage.<\/li>\n\n\n\n<li>Gaining earlier-than-projected FDA or EMA approvals\u2014by embedding regulatory fluency into clinical strategy.<\/li>\n\n\n\n<li>Achieving compliance at lower cost\u2014while navigating complex, global regulatory demands.<\/li>\n\n\n\n<li>Improving financial performance\u2014even amid the margin compression of drug pricing reform.<\/li>\n\n\n\n<li>Boosting analyst confidence and strategic clarity\u2014through outcome-driven transformation, not incrementalism.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><br>Three ways to unlock breakthrough performance<\/strong><\/h2>\n\n\n\n<p><strong>1. Rethink how R&amp;D delivers<br><\/strong>Productivity isn\u2019t just a pipeline issue. It\u2019s a design challenge.<br>We help clients streamline clinical development, align cross-functional teams, and recover critical milestones\u2014often reducing development time by over a year and doubling the number of compounds progressing to development.<\/p>\n\n\n\n<p><strong>2. Make your culture AI-ready<br><\/strong>AI is already reshaping R&amp;D\u2014from antibody design to trial simulation. But without a shift in organizational mindset, trust, and adoption, the tools alone don\u2019t deliver.<br>Breakthrough performance requires leadership alignment, cultural readiness, and intentional talent transformation.<\/p>\n\n\n\n<p><strong>3. Turn compliance into competitive advantage<br><\/strong>The Inflation Reduction Act and global reforms are rewriting the rules.<br>We help clients embed compliance into operational design, so regulatory rigour becomes an enabler of speed and credibility\u2014not a barrier.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The takeaway<\/strong><\/h2>\n\n\n\n<p>In today\u2019s biopharma landscape, transformation must be specific, urgent, and ROI-driven. There\u2019s no appetite for theoretical consulting. Only for outcomes that speak for themselves.<\/p>\n\n\n\n<p>Breakthrough results aren\u2019t optional anymore\u2014they\u2019re imperative.<\/p>\n\n\n\n<p>If that\u2019s what your next quarter demands, <a href=\"https:\/\/www.elixirr.com\/en-us\/contact\/\">we should talk<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Why now? In 2025, biopharma is caught in a squeeze. R&amp;D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a&hellip;<\/p>\n","protected":false},"author":6,"featured_media":53277,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[116],"tags":[284],"related_service":[],"related_industry":[44],"class_list":["post-53276","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","tag-research"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.1 (Yoast SEO v27.1.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly - Elixirr - USA<\/title>\n<meta name=\"description\" content=\"R&amp;D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a surge in biosimilar competition, and the stakes for innovation have never been higher.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly\" \/>\n<meta property=\"og:description\" content=\"R&amp;D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a surge in biosimilar competition, and the stakes for innovation have never been higher.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/\" \/>\n<meta property=\"og:site_name\" content=\"Elixirr - USA\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-06T08:14:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T10:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"petra\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"petra\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/\"},\"author\":{\"name\":\"petra\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#\/schema\/person\/e0fb39801ad6673e6b8b874ebcfc36f4\"},\"headline\":\"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly\",\"datePublished\":\"2025-06-06T08:14:25+00:00\",\"dateModified\":\"2025-10-31T10:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/\"},\"wordCount\":371,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg\",\"keywords\":[\"Research\"],\"articleSection\":[\"Articles\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/\",\"url\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/\",\"name\":\"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly - Elixirr - USA\",\"isPartOf\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg\",\"datePublished\":\"2025-06-06T08:14:25+00:00\",\"dateModified\":\"2025-10-31T10:02:01+00:00\",\"description\":\"R&D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a surge in biosimilar competition, and the stakes for innovation have never been higher.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage\",\"url\":\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg\",\"contentUrl\":\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg\",\"width\":2400,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.elixirr.com\/en-us\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#website\",\"url\":\"https:\/\/www.elixirr.com\/en-us\/\",\"name\":\"Elixirr - USA\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.elixirr.com\/en-us\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#organization\",\"name\":\"Elixirr\",\"alternateName\":\"Elixirr International PLC\",\"url\":\"https:\/\/www.elixirr.com\/en-us\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/11\/elixirr-logo.png\",\"contentUrl\":\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/11\/elixirr-logo.png\",\"width\":200,\"height\":200,\"caption\":\"Elixirr\"},\"image\":{\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#\/schema\/person\/e0fb39801ad6673e6b8b874ebcfc36f4\",\"name\":\"petra\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.elixirr.com\/en-us\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/dc3a8d51c8ea5862ffe640e23054f389122063065d48b608b12249b5ea33eca8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/dc3a8d51c8ea5862ffe640e23054f389122063065d48b608b12249b5ea33eca8?s=96&d=mm&r=g\",\"caption\":\"petra\"},\"url\":\"https:\/\/www.elixirr.com\/en-us\/person\/petra\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly - Elixirr - USA","description":"R&D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a surge in biosimilar competition, and the stakes for innovation have never been higher.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/","og_locale":"en_US","og_type":"article","og_title":"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly","og_description":"R&D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a surge in biosimilar competition, and the stakes for innovation have never been higher.","og_url":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/","og_site_name":"Elixirr - USA","article_published_time":"2025-06-06T08:14:25+00:00","article_modified_time":"2025-10-31T10:02:01+00:00","og_image":[{"width":2400,"height":1440,"url":"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg","type":"image\/jpeg"}],"author":"petra","twitter_card":"summary_large_image","twitter_misc":{"Written by":"petra","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#article","isPartOf":{"@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/"},"author":{"name":"petra","@id":"https:\/\/www.elixirr.com\/en-us\/#\/schema\/person\/e0fb39801ad6673e6b8b874ebcfc36f4"},"headline":"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly","datePublished":"2025-06-06T08:14:25+00:00","dateModified":"2025-10-31T10:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/"},"wordCount":371,"commentCount":0,"publisher":{"@id":"https:\/\/www.elixirr.com\/en-us\/#organization"},"image":{"@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg","keywords":["Research"],"articleSection":["Articles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/","url":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/","name":"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly - Elixirr - USA","isPartOf":{"@id":"https:\/\/www.elixirr.com\/en-us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage"},"image":{"@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg","datePublished":"2025-06-06T08:14:25+00:00","dateModified":"2025-10-31T10:02:01+00:00","description":"R&D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a surge in biosimilar competition, and the stakes for innovation have never been higher.","breadcrumb":{"@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#primaryimage","url":"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg","contentUrl":"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg","width":2400,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.elixirr.com\/en-us\/"},{"@type":"ListItem","position":2,"name":"Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly"}]},{"@type":"WebSite","@id":"https:\/\/www.elixirr.com\/en-us\/#website","url":"https:\/\/www.elixirr.com\/en-us\/","name":"Elixirr - USA","description":"","publisher":{"@id":"https:\/\/www.elixirr.com\/en-us\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.elixirr.com\/en-us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.elixirr.com\/en-us\/#organization","name":"Elixirr","alternateName":"Elixirr International PLC","url":"https:\/\/www.elixirr.com\/en-us\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.elixirr.com\/en-us\/#\/schema\/logo\/image\/","url":"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/11\/elixirr-logo.png","contentUrl":"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/11\/elixirr-logo.png","width":200,"height":200,"caption":"Elixirr"},"image":{"@id":"https:\/\/www.elixirr.com\/en-us\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.elixirr.com\/en-us\/#\/schema\/person\/e0fb39801ad6673e6b8b874ebcfc36f4","name":"petra","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.elixirr.com\/en-us\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/dc3a8d51c8ea5862ffe640e23054f389122063065d48b608b12249b5ea33eca8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dc3a8d51c8ea5862ffe640e23054f389122063065d48b608b12249b5ea33eca8?s=96&d=mm&r=g","caption":"petra"},"url":"https:\/\/www.elixirr.com\/en-us\/person\/petra\/"}]}},"card":"<article class=\"wp-component-card edwp-component wp-component-card--resource            wp-component-card--link js-card-link\n        edwp-fade-in\">\n            <figure class=\"wp-component-card__image-wrapper\">\n                            <img width=\"2400\" height=\"1440\" src=\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg\" class=\"wp-component-card__image\" alt=\"\" decoding=\"async\" srcset=\"https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440.jpg 2400w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-300x180.jpg 300w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-1024x614.jpg 1024w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-768x461.jpg 768w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-1536x922.jpg 1536w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-2048x1229.jpg 2048w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-87x52.jpg 87w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-319x191.jpg 319w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-479x287.jpg 479w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-567x340.jpg 567w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-767x460.jpg 767w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-1023x614.jpg 1023w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-1278x767.jpg 1278w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-1378x827.jpg 1378w, https:\/\/www.elixirr.com\/en-us\/wp-content\/uploads\/sites\/2\/2025\/06\/Breakthrough-or-bust2400x1440-1640x984.jpg 1640w\" sizes=\"(max-width: 2400px) 100vw, 2400px\" \/>            <div class=\"wp-component-card__preview-icon\">\n                <span class='edwp-svg '><svg width=\"47\" height=\"47\" viewBox=\"0 0 47 47\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n<g>\n<path d=\"M23.4141 0.539062C36.1232 0.539183 46.4258 10.8416 46.4258 23.5508C46.4257 36.2599 36.1231 46.5624 23.4141 46.5625C10.7049 46.5625 0.402465 36.2599 0.402344 23.5508C0.402344 10.8415 10.7048 0.539062 23.4141 0.539062ZM23.4141 1.68945C11.3606 1.68945 1.55273 11.4974 1.55273 23.5508C1.55286 35.6041 11.3607 45.4111 23.4141 45.4111C35.4673 45.411 45.2743 35.604 45.2744 23.5508C45.2744 11.4974 35.4674 1.68957 23.4141 1.68945Z\" fill=\"currentColor\"\/>\n<path d=\"M19.2841 33.6992C18.9579 33.6986 18.6374 33.6111 18.3543 33.4454C17.7167 33.0759 17.3203 32.3585 17.3203 31.5797V15.8189C17.3203 15.0379 17.7167 14.3227 18.3543 13.9531C18.6442 13.7827 18.9735 13.6951 19.3078 13.6994C19.6421 13.7037 19.9692 13.7998 20.2548 13.9776L33.4237 22.0406C33.6981 22.2166 33.9244 22.461 34.0812 22.751C34.238 23.0409 34.3203 23.3668 34.3203 23.6982C34.3203 24.0295 34.238 24.3555 34.0812 24.6454C33.9244 24.9353 33.6981 25.1798 33.4237 25.3558L20.2527 33.421C19.9604 33.6017 19.6256 33.6979 19.2841 33.6992Z\" fill=\"currentColor\"\/>\n<\/g>\n<\/svg>\n<\/span>            <\/div>\n                        <\/figure>\n        <div class=\"wp-component-card__content edwp-row-load\">\n                                    <p class=\"wp-component-card__eyebrow\">\n                Articles            <\/p>\n                <a href='https:\/\/www.elixirr.com\/en-us\/breakthrough-or-bust-why-biopharma-cant-afford-to-transform-slowly\/' class='wp-component-card__title'>\n            <h2>\n                Breakthrough or bust: Why biopharma can\u2019t afford to transform slowly\n            <\/h2>\n        <\/a>                                    <div class=\"wp-component-card__description\">\n                    Why now? In 2025, biopharma is caught in a squeeze. R&amp;D costs are soaring. Timelines are slipping. Regulatory reform is tightening margins. Add the expiry of blockbuster patents and a&hellip;                <\/div>\n                                                    <div class=\"wp-component-card__meta\">\n                                            <p class=\"wp-component-card__date\">\n                            06 June 2025                        <\/p>\n                                                                <div class=\"wp-component-card__terms\">\n                                                                                                                                                    <div class=\"wp-component-tags edwp-component\">\n                        <div class=\"wp-component-tags__tag\">\n                Healthcare &amp; Pharmaceuticals            <\/div>\n                <\/div>\n                        <\/div>\n                                    <\/div>\n                                                    <div class=\"wp-component-card__button-wrapper\">\n                    <button class=\"btn btn--link arrow wp-component-card__button\">\n                                                                            Read more                                                                            <span class='edwp-svg '><svg width=\"20\" height=\"20\" viewBox=\"0 0 20 20\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n<g id=\"Lg\">\n<path id=\"Vector\" d=\"M1.12509 9.50162H15.8648L9.43259 3.06941C9.374 3.0113 9.3275 2.94216 9.29576 2.86599C9.26403 2.78981 9.24769 2.70811 9.24769 2.62559C9.24769 2.54307 9.26403 2.46137 9.29576 2.38519C9.3275 2.30902 9.374 2.23988 9.43259 2.18177C9.54971 2.06535 9.70814 2 9.87328 2C10.0384 2 10.1969 2.06535 10.314 2.18177L17.8151 9.6829C17.8737 9.74101 17.9202 9.81014 17.9519 9.88632C17.9837 9.96249 18 10.0442 18 10.1267C18 10.2092 17.9837 10.2909 17.9519 10.3671C17.9202 10.4433 17.8737 10.5124 17.8151 10.5705L10.314 18.0717C10.1975 18.1871 10.0404 18.2522 9.87641 18.2529C9.79414 18.2534 9.71259 18.2376 9.63643 18.2065C9.56027 18.1754 9.491 18.1296 9.43259 18.0717C9.374 18.0135 9.3275 17.9444 9.29576 17.8682C9.26403 17.7921 9.24769 17.7104 9.24769 17.6278C9.24769 17.5453 9.26403 17.4636 9.29576 17.3874C9.3275 17.3113 9.374 17.2421 9.43259 17.184L15.8711 10.7518H1.12509C0.959309 10.7518 0.800312 10.686 0.683084 10.5687C0.565857 10.4515 0.5 10.2925 0.5 10.1267C0.5 9.96093 0.565857 9.80193 0.683084 9.68471C0.800312 9.56748 0.959309 9.50162 1.12509 9.50162Z\" fill=\"#1D0F25\"\/>\n<\/g>\n<\/svg>\n<\/span>                                            <\/button>\n                <\/div>\n                                            <\/div>\n<\/article>\n","_links":{"self":[{"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/posts\/53276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/comments?post=53276"}],"version-history":[{"count":3,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/posts\/53276\/revisions"}],"predecessor-version":[{"id":56301,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/posts\/53276\/revisions\/56301"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/media\/53277"}],"wp:attachment":[{"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/media?parent=53276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/categories?post=53276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/tags?post=53276"},{"taxonomy":"related_service","embeddable":true,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/related_service?post=53276"},{"taxonomy":"related_industry","embeddable":true,"href":"https:\/\/www.elixirr.com\/en-us\/wp-json\/wp\/v2\/related_industry?post=53276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}